PsOPsA Hub cover art

PsOPsA Hub

PsOPsA Hub

By: Scientific Education Support
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The PsOPsA Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. Our aim is to enhance knowledge in psoriasis and psoriatic arthritis, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
Biological Sciences Hygiene & Healthy Living Personal Development Personal Success Physical Illness & Disease Science
Episodes
  • Exploring the impact of obesity on psoriatic arthritis
    Oct 20 2026

    During the PsOPsA Hub Steering Committee meeting on August 24, 2026, key opinion leaders met to discuss the impact of obesity on psoriatic arthritis (PsA). The discussion was chaired by Paolo Gisondi and featured Laura Coates, Jody Quinn, and Yukari Okubo.


    Coates presented an overview of obesity in psoriatic disease and key efficacy and safety results from the phase III TOGETHER-PsA trial of ixekizumab + tirzepatide in patients with PsA and overweight/obesity.


    This educational resource is independently supported by Lilly. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    39 mins
  • Clinical factors guiding the choice of IL-23 vs IL-17 inhibitors in psoriatic disease
    Nov 7 2025

    The IL-23/IL-17 axis is central to the pathogenesis of psoriatic disease, and therapeutic targeting of these pathways has led to a paradigm shift in treatment approaches. However, it is not always clear whether an IL-23 or an IL-17 inhibitor would be more appropriate.


    The PsOPsA Hub spoke with Peter Nash, Griffith University, Queensland, AU. We asked, What clinical factors guide your decision to initiate an IL-23 or IL-17 inhibitor in patients with psoriatic disease?


    This educational resource is independently supported by UCB. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    4 mins
  • Dual inhibition of IL-17A and IL-17F in psoriatic disease
    Sep 18 2025

    During the PsOPsA Hub Steering Committee Meeting on July 16, 2025, Peter Nash, Griffith University, Queensland, AU, chaired a discussion on dual inhibition of IL-17A and IL-17F in psoriatic disease. The discussion also featured Paolo Gisondi, Ulrich Mrowietz, Yukari Okubo, and Jody Quinn.


    Key learnings:

    Treatment decisions in psoriatic disease are guided by both administrative and clinical factors.

    o Administratively, biosimilars are recommended as first choice due to cost constraints. If treatment fails, other classes such as IL-23 (p19) or IL-17 inhibitors may be considered.

    o Clinically, treatment decisions are mainly driven by disease severity. Dual IL-17A/F inhibitors are favored for patients with severe, resistant, or diffuse psoriasis, as well as in those presenting with arthralgia – even in the absence of a confirmed PsA diagnosis – compared with adalimumab and other agents.


    In Germany, all biologics are accessible, including bimekizumab.

    o IL-17 inhibitors, particularly bimekizumab and ixekizumab, are the first choice for PsA.

    o Bimekizumab is also preferred after failure of other biologics or other treatments, and in severe skin disease.

    o Candida infections, especially folliculitis, remain a concern, particularly during the first year of treatment. Management is further complicated by the need to avoid azole antifungals, such as fluconazole, due to CYP450-mediated drug–drug interactions.

    o Despite this, bimekizumab remains a highly effective option for skin, joint, and nail involvement.


    In Japan, IL-17A or IL-23 inhibitors are typically used as first-line therapy for severe skin disease, while dual IL-17A/F inhibitors are reserved for use after treatment failure. For difficult-to-manage PsA, dual inhibitors are often preferred as first-line therapy.

    o Real-world incidence of Candida appears to be reduced with consistent oral hygiene.


    Patient experience of biologics found bimekizumab to give relief from psoriatic pain, and scalp and hand psoriasis, but also suggested that treatments spaced beyond 4 weeks may be to be less effective.


    This independent educational activity was supported by UCB. All content was developed independently. The funder was allowed no influence on the content of this activity.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    23 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.